Insmed: Fourth Quarter Financial Highlights

Insmed Inc. Reports Fourth Quarter Financial Results

Insmed Inc., headquartered in Bridgewater, New Jersey, announced on Thursday that it recorded a net loss of $328.5 million for the fourth quarter.

The loss equated to $1.54 per share, according to the company's statement.

This performance fell short of analysts’ projections. According to Zacks Investment Research, nine analysts had anticipated a smaller loss of $1.07 per share.

The biopharmaceutical firm, which specializes in inhaled therapies for rare lung conditions, generated $263.8 million in revenue during the quarter. This figure was slightly below the $263.9 million forecasted by four analysts surveyed by Zacks.

For the full year, Insmed reported a total loss of $1.28 billion, or $6.42 per share, with annual revenue reaching $606.4 million.